Here’s a question that frustrates patients and providers alike: if TMS is a proven, safe, Health Canada-approved treatment for depression, why isn’t it available on every corner, and why isn’t it simply covered? The answer says a lot about how our health system adopts new treatments, and there’s reason for cautious optimism.
The treatment is proven. The system is slow.
Depression is a serious illness and a leading cause of disability in Canada. TMS has been Health Canada approved for treating it since 2002, with high remission and response rates and next to no side effects. On the clinical evidence, this is not a fringe treatment, more than 30 systematic reviews and meta-analyses have examined TMS for depression, most involving patients with some degree of treatment resistance.
So the barrier isn’t whether it works. The barrier is access: how a treatment moves from “approved and effective” to “available and funded where you live.”
The funding gap
This is the crux of it. A treatment being approved is not the same as a treatment being publicly funded, and in Canada those two things can be separated by years.
BC offers a clear example. In February 2022, the province’s Ministry of Health Technology Assessment Committee recommended provincial funding of TMS for depression, genuinely good news. But at this time, it remains a recommendation rather than active funding. This isn’t unique to BC: Ontario received the same recommendation back in 2016, and TMS still isn’t publicly funded there either. Recommendations, it turns out, can sit for a long time before they become coverage.
In the meantime, TMS remains available through private clinics. As a physician-prescribed treatment, it may be eligible under a Health Spending Account and can qualify as an eligible medical expense with the CRA for income-tax purposes, which softens the cost for some, but doesn’t erase the underlying access gap.
Why geography matters too
Beyond funding, there’s simple availability. Specialized treatments tend to cluster in large urban centres, which can leave people in smaller communities and on the Islands facing long drives or long waits. Part of why we operate on Vancouver Island is precisely this: proven treatment shouldn’t only be available to people who happen to live next to a major hospital.
What’s changing
There is movement. The fact that BC’s assessment committee recommended funding at all reflects a growing official recognition of TMS’s value. As the evidence base continues to deepen and more clinics operate across the country, both the funding conversation and the availability picture are slowly shifting in the right direction. It’s slower than anyone struggling with depression would like, but the direction is encouraging.
The honest caveats
We’re a clinic, so it’s fair to note our vantage point. But the facts here aren’t in dispute: the treatment is approved and effective, funding lags behind approval, and access varies by geography. We’d genuinely welcome public funding, it would help the people we exist to serve. Until then, the honest thing is to be transparent about cost, coverage, and what your realistic options are today.
The takeaway
Effective depression treatment exists. The harder problem is getting it to everyone who needs it, and that’s a systems problem, not a scientific one. If you’re on Vancouver Island and want to understand your options, including cost and possible tax or spending-account eligibility, our team is happy to lay it out plainly.
This article is for general information and reflects funding and policy status as described on our site at time of writing; these can change. It is not a substitute for individual medical or financial advice.